Lazana I, Gkirkas K, Konstantellos I, Chatzidimitriou C, et al. Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity. Bone Marrow Transplant 2025 Oct 23. doi: 10.1038/s41409-025-02736.
PMID: 41131404